Galera Therapeutics, Inc. (GRTX) |
|
1.41 -0.04 (-2.76%)
|
08-18 07:41 |
|
Open: |
1.45 |
Pre. Close: |
1.45 |
|
High:
|
1.46 |
Low:
|
1.41 |
|
Volume:
|
10,476 |
Market Cap:
|
38(M) |
|
|
|
|
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.46 - 1.47 |
1.47 - 1.48 |
|
Low:
|
1.39 - 1.4 |
1.4 - 1.41 |
|
Close:
|
1.4 - 1.41 |
1.41 - 1.42 |
|
Technical analysis |
as of: 2022-08-17 4:23:49 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 1.75 One year: 2.04 |
| Support: |
Support1: 1.26 Support2: 1.12 |
| Resistance: |
Resistance1: 1.5 Resistance2: 1.75 |
| Pivot: |
1.26  |
| Moving Average: |
MA(5): 1.41 MA(20): 1.24
MA(100): 1.56 MA(250): 2.89 |
| MACD: |
MACD(12,26): 0 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 83.8 %D(3): 86.8 |
| RSI: |
RSI(14): 61.4 |
| 52-week: |
High: 9.31 Low: 1.12 |
| Average Vol(K): |
3-Month: 85 (K) 10-Days: 73 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GRTX ] has closed below upper band by 17.6%. Bollinger Bands are 1.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Fri, 12 Aug 2022
Insiders at Galera Therapeutics, Inc. (NASDAQ:GRTX) recouped some losses this week after buying this year, still down US$28k - Simply Wall St
Sun, 29 May 2022
Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology - MyChesCo
Mon, 16 May 2022
Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates - GlobeNewswire
Mon, 02 May 2022
Galera's avasopasem reduces esophagitis in patients receiving chemoradiotherapy - Seeking Alpha
Wed, 27 Apr 2022
Galera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - Yahoo Finance
Tue, 19 Oct 2021
Galera Announces Results of Phase 3 ROMAN Trial of Avasopasem for Radiotherapy-Induced Severe Oral Mucositis - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
27 (M) |
| Shares Float |
18 (M) |
|
% Held by Insiders
|
5.5 (%) |
|
% Held by Institutions
|
45.3 (%) |
|
Shares Short
|
488 (K) |
|
Shares Short P.Month
|
557 (K) |
Stock Financials |
|
EPS
|
-2.95 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-2.64 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-61 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-2.55 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-64 (M) |
|
Levered Free Cash Flow
|
-43 (M) |
Stock Valuations |
|
PE Ratio
|
-0.48 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
-0.54 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.6 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
